Docetaxel in advanced non-small cell lung cancer

References

• Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin.54(1), 8–29 (2004).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer94(2), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Cox JD, Ginsberg RJ et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt)10(Suppl. 11), 81–111 (1996).
   PubMedGoogle Scholar
• American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J. Clin. Oncol.14(2), 671–679 (1996).
   PubMed Web of Science ®Google Scholar
• Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst.83(4), 288–291 (1991).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs55(1), 5–30 (1998).
   PubMed Web of Science ®Google Scholar
• Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol.17(3), 1061–1070 (1999).
   PubMed Web of Science ®Google Scholar
• Guidolin D, Vacca A, Nussdorfer GG, Ribatti D. A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc. Res.67(2), 117–124 (2004).
   PubMedGoogle Scholar
• Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of anti-angiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer104(1), 121–129 (2003).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treat. Rev.29(5), 407–415 (2003).
   PubMed Web of Science ®Google Scholar
• Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976 NSC 628503) given as a short intravenous infusion. Cancer Res.53(5), 1037–1042 (1993).
   PubMed Web of Science ®Google Scholar
• Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther.75(5), 448–454 (2004).
   PubMed Web of Science ®Google Scholar
• Synold T, Newman E, Lenz H-J et al. Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD). Proc. Am. Soc. Clin. Oncol.18, 168a (1999) (Abstract 643).
   Google Scholar
• Pronk LC, Schellens JH, Planting AS et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. Oncol.15(3), 1071–1079 (1997).
   PubMedGoogle Scholar
• Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.15(2), 750–758 (1997).
   PubMed Web of Science ®Google Scholar
• Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese co-operative study. J. Clin. Oncol.14(5), 1649–1655 (1996).
   PubMed Web of Science ®Google Scholar
• Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer70(2), 384–387 (1994).
   PubMed Web of Science ®Google Scholar
• Miller VA, Rigas JR, Francis PA et al. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer75(4), 968–972 (1995).
   PubMed Web of Science ®Google Scholar
• Latreille J, Gelmon KA, Hirsh V et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest. New Drugs16(3), 265–270 (1998).
   PubMedGoogle Scholar
• Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol.12(6), 1238–1244 (1994).
   PubMed Web of Science ®Google Scholar
• Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with Stage III and IV non-small-cell lung cancer. J. Clin. Oncol.12(6), 1232–1237 (1994).
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer27(3), 145–157 (2000).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol.22(2), 330–353 (2004).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol.18(12), 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18(10), 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized Phase III trial. Lung Cancer43(2), 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol.16(6), 2164–2168 (1998).
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer92(8), 2158–2163 (2001).
   PubMed Web of Science ®Google Scholar
• Ardizzoia A, Acquati M, Fagnani D et al. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian Phase II study. Lung182(1), 1–8 (2004).
   PubMedGoogle Scholar
• Esteban E, Gonzalez de Sande L, Fernandez Y et al. Prospective randomised Phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann. Oncol.14(11), 1640–1647 (2003).
   PubMedGoogle Scholar
• Petrioli R, Pozzessere D, Messinese S et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer39(1), 85–89 (2003).
   PubMedGoogle Scholar
• Serke M, Schoenfeld N, Loddenkemper R. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial. Anticancer Res.24(2C), 1211–1216 (2004).
   PubMedGoogle Scholar
• Rossi D, Graziano F, Ugolini M et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a Phase II study. Tumori90(1), 50–53 (2004).
   PubMedGoogle Scholar
• Vazquez S, Grande C, Amenedo M et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a Phase II study of the Galician Lung Cancer Group (GGCP 006–00). Anticancer Drugs15(5), 489–494 (2004).
   PubMedGoogle Scholar
• Chen Y-M, Shih J-F, Tsai C-M, Perng R-P, Whang-Peng J. Preliminary report of a randomized trial of different docetaxel schedules in non-small cell lung cancer patients failing previous chemotherapy. J. Clin. Oncol.22(Suppl. 14), 644s (2004) (Abstract 7112).
   Google Scholar
• Gridelli C, Illiano A, Salvagni S et al. Effect on quality-of-life (QoL) of weekly vs. 3-weekly docetaxel (D) in second-line treatment of advanced non-small-cell lung cancer. The DISTAL randomized Phase 3 study. Proc. Am. Soc. Clin. Oncol.22, 625 (2003) (Abstract 2515).
   Google Scholar
• Camps C, Massuti B, Jimenez AM et al. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) Phase III trial. Proc. Am. Soc. Clin. Oncol.22, 625 (2003) (Abstract 2514).
   Google Scholar
• Schuette W, Nagel S, Serke M, Lautenschlaeger C, Hans K, Lorenz C. Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: results of a randomized Phase III study. J. Clin. Oncol.22(Suppl. 14), 625s (2004) (Abstract 7036).
   Google Scholar
• Georgoulias V, Ardavanis A, Agelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter Phase III trial. J. Clin. Oncol.22(13), 2602–2609 (2004).
   PubMed Web of Science ®Google Scholar
• Groen H, Schramel FM, Van der Hoeven JJM et al. Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of a multicenter Phase III trial. Proc. Am. Soc. Clin. Oncol.22, 623 (2003) (Abstract 2505).
   Google Scholar
• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346(2), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.21(16), 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with Stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol.22(2), 254–261 (2004).
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Dobbs TW, Einzig AI et al. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter Phase II study. Cancer Chemother. Pharmacol.53(5), 439–444 (2004) .
   PubMed Web of Science ®Google Scholar
• Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a Phase II study in Caucasian and Asian patients. Ann. Oncol.14(3), 449–454 (2003).
   PubMed Web of Science ®Google Scholar
• Giannakakis T, Kakolyris S, Theodoropoulos E et al. A multicenter Phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res.22(6B), 3743–3748 (2002).
   PubMedGoogle Scholar
• Jahanzeb M, Sarna G, Hirsch R et al. Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a Phase II study. Anticancer Res.24(2C), 1239–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Lorigan P, Booton R, Ashcroft L et al. Randomised Phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) – final results of a British Thoracic Oncology Group (BTOG) trial. J. Clin. Oncol.22(Suppl. 14), 632s (2004) (Abstract 7066).
   Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet357(9267), 1478–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Popa IE, Stewart K, Smith FP, Rizvi NA. A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer95(8), 1714–1719 (2002).
   PubMedGoogle Scholar
• Israel V, Tagawa ST, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC). Invest. New Drugs22(3), 291–297 (2004).
   PubMedGoogle Scholar
• Rocha Lima CM, Rizvi NA, Zhang C et al. Randomized Phase II trial of gemcitabine plus irinotecan or docetaxel in Stage IIIB or Stage IV NSCLC. Ann. Oncol.15(3), 410–418 (2004).
   PubMedGoogle Scholar
• Kakolyris S, Tsiafaki X, Agelidou A et al. Preliminary results of a multicenter randomized Phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol.21, 296a (2002) (Abstract 1182).
   Google Scholar
• Kosmas C, Tsavaris N, Kalofonos HP. Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent Phase II studies. Med. Sci. Monit.8(6), PI58–PI63 (2002).
   PubMedGoogle Scholar
• Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am. J. Clin. Oncol.25(5), 509–512 (2002).
   PubMedGoogle Scholar
• Niho S, Kubota K, Goto K et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a Phase I/II trial. Cancer Chemother. Pharmacol.52(1), 19–24 (2003).
   PubMedGoogle Scholar
• Takeda K, Negoro S, Tamura T et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): results of a JCOG randomized trial (JCOG0104). J. Clin. Oncol.22(Suppl. 14), 625s (2004) (Abstract 7034).
   Google Scholar
• Kouroussis C, Mavroudis D, Kakolyris S et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer44(3), 363–368 (2004).
   PubMed Web of Science ®Google Scholar
• Pectasides D, Farmakis D, Pectasides M et al. Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized Phase II trial. J. Clin. Oncol.22(Suppl. 14), 625s (2004) (Abstract 7033).
   Google Scholar
• Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs21(4), 435–443 (2003).
   PubMed Web of Science ®Google Scholar
• Frasci G, Comella P, Thomas R et al. Biweekly docetaxel–irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A Phase I study. Cancer Chemother. Pharmacol.53(1), 25–32 (2004).
   PubMedGoogle Scholar
• Grossi F, Belvedere O, Rossetto C et al. Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): an Alpe Adria Thoracic Oncology Multidisciplinary group Phase II study (ATOM 007). J. Clin. Oncol.22(Suppl. 14), 706S (2004) (Abstract 7363).
   PubMedGoogle Scholar
• Keresztes RS, Socinski MA, Bonomi P, Chen A, Hart L, Lilenbaum RC. Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 650S (2004) (Abstract 7137).
   Google Scholar
• Ziotopoulos P, Chandrinos V, Samaras N et al. A Phase II study of docetaxel plus irinotecan (DOCIRI) in chemo-naive patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 682S (2004) (Abstract 7267).
   Google Scholar
• Ramalingam S, Dobbs TW, Coke DE, Wojtowicz-Praga S, Belani CP. Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): results of a multi-center, Phase II study. J. Clin. Oncol.22(Suppl. 14), 690S (2004) (Abstract 7298).
   Google Scholar
• Page RD, Smith FP, Geils GF et al. Prospective multi-center Phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 650S (2004) (Abstract 7138).
   Google Scholar
• Pectasides D, Aspropotamitis A, Halikia A et al. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol.17(12), 3816–3821 (1999).
   PubMedGoogle Scholar
• Pectasides D, Visvikis A, Kouloubinis A et al. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a Phase II study. Eur. J. Cancer38(9), 1194–1200 (2002).
   PubMedGoogle Scholar
• Kosmas C, Tsavaris NB, Makatsoris T et al. A Phase I–II study of docetaxel–ifosfamide–cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Int. J. Cancer98(1), 141–147 (2002).
   PubMed Web of Science ®Google Scholar
• Bessho A, Takata I, Shinkai T et al. A triplet chemotherapy with cisplatin, docetaxel and irinotecan in patients with Stage IIIB/IV non-small-cell lung cancer (NSCLC): a Phase I/II study of Okayama Lung Cancer Study Group (OLCSG). Proc. Am. Soc. Clin. Oncol.22, 660 (2003) (Abstract 2654).
   Google Scholar
• Perol M, Lena H, Thomas P et al. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin–vinorelbine with a cisplatin–vinorelbine control group in patients with Stage IV non-small-cell lung cancer: GFPC 97.01 study. Ann. Oncol.13(5), 742–747 (2002).
   PubMedGoogle Scholar
• Yamamoto N, Fukuoka M, Negoro SI et al. Randomised Phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br. J. Cancer90(1), 87–92 (2004).
   PubMed Web of Science ®Google Scholar
• Rigas JR, Carey M, Cole B et al. Multicenter Web-based Phase III study to test the survival equivalence of non-platinum-based (NPB) vs. platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): the Dartmouth NPB Chemotherapy Trial (D0112). J. Clin. Oncol.22(Suppl. 14), 634s (2004) (Abstract 7071).
   PubMedGoogle Scholar
• Langer CJ, Vangel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 YRS) with NSCLC do as well as younger pts (<70). Proc. Am. Soc. Clin. Oncol.22, 639 (2003) (Abstract 2571).
   Google Scholar
• Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Co-operative Oncology Group 5592, a randomized trial. J. Natl Cancer Inst.94(3), 173–181 (2002).
   PubMed Web of Science ®Google Scholar
• Fossella FV, Belani CP, Group TS. Phase III study (TAX 326) of docetaxel–cisplatin (DC) and docetaxel–carboplatin (DCb) versus vinorelbine–cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): analyses in elderly patients. Proc. Am. Soc. Clin. Oncol.22, 629 (2003) (Abstract 2528).
   Google Scholar
• Minami H, Ohe Y, Niho S et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J. Clin. Oncol.22(14), 2901–2908 (2004).
   PubMed Web of Science ®Google Scholar
• Ten Tije AJ, Verweij J, Carducci MA, Rogers T, Dawkins FW, Baker SD. Prospective evaluation of the pharmacokinetic (PK) and toxicity profile of docetaxel in the elderly. J. Clin. Oncol.22(Suppl. 14), 739s (2004) (Abstract 8043).
   Google Scholar
• Sweeney CJ, Zhu J, Sandler AB et al. Outcome of patients with a performance status of 2 in Eastern Co-operative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer92(10), 2639–2647 (2001).
   PubMed Web of Science ®Google Scholar
• Sandbach JF, Weissman C, Brooker R, Ilegbodu D, Asmar L. A Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age < 65 and performance status 2. J. Clin. Oncol.22(Suppl. 14), 646s (2004) (Abstract 7122).
   Google Scholar
• Lilenbaum RC, Rubin M, Samuel J et al. A Phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 630s (2004) (Abstract 7057).
   Google Scholar
• Hesketh PJ, Chansky K, Lau DH, Crowley J, Gandara DR, Group SO. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG Phase II trial (S0027). J. Clin. Oncol.22(Suppl. 14), 630s (2004) (Abstract 7056).
   Google Scholar
• Hainsworth JD, Erland JB, Barton JH et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network Phase II trial. Clin. Lung Cancer5(1), 33–38 (2003).
   PubMedGoogle Scholar
• Kim ES, Mauer AM, Tran HT et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc. Am. Soc. Clin. Oncol.22, 642 (2003) (Abstract 2581).
   Google Scholar
• Fandi A, Gatzemeier U, Smith R, Averbuch S, Manegold C. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol.22, 655 (2003) (Abstract 2635).
   Google Scholar
• Rixe O, Lemarie E, Chomy F et al. Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell-lung cancer (NSCLC): clinical results and biological monitoring. Proc. Am. Soc. Clin. Oncol.22, 661 (2003) (Abstract 2659).
   Google Scholar
• Kimura T, Mahaffey CM, Pryde BJ et al. Apoptotic effects of the docetaxelOSI-774 combination in non-small cell lung carcinoma (NSCLC) cells. J. Clin. Oncol.22(Suppl. 14), 652s (2004) (Abstract 7143).
   Google Scholar
• Fanucchi MP, Belt RJ, Fossella FV et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): preliminary results. J. Clin. Oncol.22(Suppl. 14), 643s (2004) (Abstract 7107).
   Google Scholar
• Robert F, Busby E, Marques MB, Reynolds RE, Carey DE. Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer42(2), 237–245 (2003).
   PubMedGoogle Scholar
• Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res.10(12 Pt 2), 4270S–4275S (2004).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Frankel SR. Oblimersen sodium (Genasense Bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin. Cancer Res.10(12 Pt 2), 4245S–4248S (2004).
   PubMed Web of Science ®Google Scholar
• Ross HJ, Rudin CM, Hart LL et al. Randomized Phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 626S (2004) (Abstract 7039).
   Google Scholar
• Nugent FW, Graziano S, Levitan N et al. Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractory non-small cell lung cancer (NSCLC): promising progression-free survival in a Phase II study. Proc. Am. Soc. Clin. Oncol.22, 671 (2003) (Abstract 2697).
   Google Scholar
• Chaplen RA, Kalemkerian GP, Wozniak A et al. Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 641S (2004) (Abstract 7102).
   Google Scholar
• Gadgeel SM, Thatai L, Kraut M et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Proc. Am. Soc. Clin. Oncol.22, 684 (2003) (Abstract 2749).
   Google Scholar
• Winton TL, Livingston R, Johnson D et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected Stage 1B and II non-small cell lung cancer (NSCLC) Intergroup JBR.10. J. Clin. Oncol.22(Suppl. 14), 621S (2004) (Abstract 7018).
   Google Scholar
• Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol. 9633. J. Clin. Oncol.22(Suppl. 14), 621S (2004) (Abstract 7019).
   Google Scholar